Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10)
Inventors
Narain, Niven Rajin • McCook, John Patrick
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10351915-B2
Publication Date
2019-07-16
Expiration Date
Abstract
Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.
Core Innovation
The invention relates to treating pancreatic cancer in a human by administering Coenzyme Q10 (CoQ10) in its oxidized form. The method includes administering CoQ10 so that treatment occurs and so that administration results in an increase of CoQ10 in the oxidized form in the human. The CoQ10 used has a purity between 95% and 100% and is administered intravenously at a dose of at least 5 mg/kg.
The document characterizes oxidized CoQ10 as a mitochondrial Epi-shifter/MIM and emphasizes mitochondrial localization. It also emphasizes that the predominantly oxidized form is quantified, including by LC-MS/MS, and is associated with apoptosis and modulation of gene and protein pathways.
The biological rationale includes experiments that identify oxidized CoQ10 effects on pathways including apoptosis, oxidative stress, and metabolism/insulin/angiogenesis. Gene and protein changes are reported using arrays and proteomics approaches, including proteomics, antibody microarray, and Real-Time PCR arrays, with interaction with specific proteins and genes selected from tables referenced in the document.
Claims Coverage
The claim coverage identifies 1 independent claim directed to pancreatic cancer treatment in a human using intravenously administered oxidized Coenzyme Q10 at specified purity and a minimum dose that increases oxidized CoQ10 in the human. Dependent claims refine the method with specified protein and gene interactions, optional adjunct treatment regimens, and combination therapy with an additional therapeutic agent, including prior administration and gemcitabine as the chemotherapeutic additional agent.
Intravenous oxidized CoQ10 treatment of pancreatic cancer
A method for treating pancreatic cancer in a human by intravenously administering Coenzyme Q10 (CoQ10) in its oxidized form at a dose of at least 5 mg/kg, with CoQ10 purity between 95% and 100%, such that treatment occurs and administration results in an increase of CoQ10 in the oxidized form in the human.
Mechanism via interaction with selected proteins and genes
The method further includes that Coenzyme Q10 interacts with a specified protein chosen from a listed set and with one or more genes listed in specified tables (Tables 2-4 and 6-28).
Adjunct treatment regimen selection
The method further includes using a treatment regimen selected from surgery, radiation, hormone therapy, antibody therapy, growth factors therapy, cytokines therapy, or chemotherapy.
Combination administration with an additional therapeutic agent
The method further includes administering Coenzyme Q10 together with an additional therapeutic agent.
Prior administration timing in combination therapy
In the combination method, Coenzyme Q10 is administered before administering the additional therapeutic agent.
Gemcitabine as the chemotherapeutic additional agent
The chemotherapeutic agent used as the additional therapeutic agent is gemcitabine.
Overall, the claims coverage centers on intravenous administration of oxidized CoQ10 meeting purity and dosing constraints for treating pancreatic cancer, with dependent claims narrowing the mechanism to interactions with selected proteins and genes. Additional dependent claims cover optional adjunct regimens and combination therapy via co-administration, including prior administration timing and gemcitabine as a chemotherapeutic option.
Stated Advantages
Selectively induces apoptosis in cancer cells.
Enables a metabolic shift from glycolysis toward mitochondrial oxidative phosphorylation.
Modulates multiple pathways including apoptosis or cancer biology, glycolysis or metabolism, molecular transport, and signaling.
Documented Applications
Treating pancreatic cancer in a human by increasing oxidized CoQ10 in the human after intravenous administration.
Combination therapy contexts for pancreatic cancer, including optional combination with chemotherapy (gemcitabine) and other adjunct regimens such as surgery, radiation, hormone therapy, antibody therapy, growth factors therapy, cytokines therapy.
Interested in licensing this patent?